Texas Retina’s Ashkan M. Abbey, MD, presented “The Real-World Efficacy and Safety of Faricimab in Neovascular Age-Related Macular Degeneration: The TRUCKEE Study – 2.5 Year Results” at the 57thAnnual Scientific Meeting of The Retina Society held September 11-15, in Lisbon, Portugal.

About Faricimab and the TRUCKEE Study
A collaborative clinician-directed and organized study across multiple sites in the U.S., the TRUCKEE study is evaluating faricimab (Vabysmo), a monoclonal antibody delivered via intravitreal injection to treat adults with neovascular (wet) age-related macular degeneration (AMD). Approved by the U.S. Food and Drug Administration (FDA) in January 2022, faricimab targets two pathways of neovascular AMD: vascular endothelial growth factor A (VEGF-A) and angiopoetin-2 (Ang-2). Both promote abnormal growth and leakage of blood vessels in the eye.

Latest TRUCKEE Study Results
During his presentation, Dr. Abbey reported the following key findings:

  • In a real-world setting, with 17,829 injections in 3,607 eyes, faricimab continued to demonstrate rapid improvement in all anatomic parameters in both treatment naïve and previously treated patients.
  • The benefit of faricimab increased with continuous treatments, with improvements in anatomy and extension of treatment intervals.
  • Patients switched to faricimab from aflibercept had interval extension of almost 3 weeks after 9 faricimab injections.
  • Faricimab demonstrated a low rate of intraocular inflammation (IOI)/endophthalmitis with one report of bilateral non-occlusive vasculitis. All events resolved, and vision returned to baseline in all cases.

“It’s exciting to see that faricimab continues to demonstrate its ability to improve vision, reduce central subfield thickness and control retinal fluid over time while also allowing patients to enjoy longer intervals between their injections,” shares Dr. Abbey. “We’re seeing positive results in both patients who receive faricibmab as the initial treatment for their wet AMD as well as for those who have switched to faricimab from other anti-VEGF injections. While we will continue to study the durability and safety in real-world practice, we’re thrilled with these results and what they mean for our patients.”

Texas Retina’s director of clinical research for Dallas, Dr. Abbey cares for patients in the Dallas Main and Rockwall offices. You can learn more about him here.

 About the The Retina Society
The Retina Society was founded in 1968 exclusively for educational and scientific purposes concerning the diagnosis, care and treatment of diseases and injuries to the retina.